NASDAQ
MGNX

MacroGenics Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

MacroGenics Inc Stock Price

Vitals

Today's Low:
$4.94
Today's High:
$5.47
Open Price:
$5.42
52W Low:
$2.935
52W High:
$7.9
Prev. Close:
$5.42
Volume:
556104

Company Statistics

Market Cap.:
$335.77 million
Book Value:
2.77
Revenue TTM:
$152.46 million
Operating Margin TTM:
-63.2%
Gross Profit TTM:
$-62469000
Profit Margin:
4.89%
Return on Assets TTM:
-23%
Return on Equity TTM:
4.74%

Company Profile

MacroGenics Inc had its IPO on 2013-10-10 under the ticker symbol MGNX.

The company operates in the Healthcare sector and Biotechnology industry. MacroGenics Inc has a staff strength of 357 employees.

Stock update

Shares of MacroGenics Inc opened at $5.42 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $4.94 - $5.47, and closed at $4.94.

This is a -8.86% slip from the previous day's closing price.

A total volume of 556,104 shares were traded at the close of the day’s session.

In the last one week, shares of MacroGenics Inc have increased by +1.65%.

MacroGenics Inc's Key Ratios

MacroGenics Inc has a market cap of $335.77 million, indicating a price to book ratio of 3.1198 and a price to sales ratio of 4.079.

In the last 12-months MacroGenics Inc’s revenue was $152.46 million with a gross profit of $-62469000 and an EBITDA of $-84490000. The EBITDA ratio measures MacroGenics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, MacroGenics Inc’s operating margin was -63.2% while its return on assets stood at -23% with a return of equity of 4.74%.

In Q2, MacroGenics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 49.5%.

MacroGenics Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
45.1667
PEG
0.01

Its diluted EPS in the last 12-months stands at $0.12 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0.01. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into MacroGenics Inc’s profitability.

MacroGenics Inc stock is trading at a EV to sales ratio of 3.0927 and a EV to EBITDA ratio of -1.5663. Its price to sales ratio in the trailing 12-months stood at 4.079.

MacroGenics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$305.65 million
Total Liabilities
$68.21 million
Operating Cash Flow
$-113476000.00
Capital Expenditure
$286000
Dividend Payout Ratio
0%

MacroGenics Inc ended 2024 with $305.65 million in total assets and $0 in total liabilities. Its intangible assets were valued at $305.65 million while shareholder equity stood at $171.54 million.

MacroGenics Inc ended 2024 with $0 in deferred long-term liabilities, $68.21 million in other current liabilities, 619000.00 in common stock, $-1074234000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $108.76 million and cash and short-term investments were $240.35 million. The company’s total short-term debt was $4,161,000 while long-term debt stood at $0.

MacroGenics Inc’s total current assets stands at $240.35 million while long-term investments were $0 and short-term investments were $131.59 million. Its net receivables were $6.41 million compared to accounts payable of $3.80 million and inventory worth $1.44 million.

In 2024, MacroGenics Inc's operating cash flow was $-113476000.00 while its capital expenditure stood at $286000.

Comparatively, MacroGenics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$4.94
52-Week High
$7.9
52-Week Low
$2.935
Analyst Target Price
$12.38

MacroGenics Inc stock is currently trading at $4.94 per share. It touched a 52-week high of $7.9 and a 52-week low of $7.9. Analysts tracking the stock have a 12-month average target price of $12.38.

Its 50-day moving average was $5.06 and 200-day moving average was $5.86 The short ratio stood at 7.78 indicating a short percent outstanding of 0%.

Around 268.7% of the company’s stock are held by insiders while 9463.8% are held by institutions.

Frequently Asked Questions About MacroGenics Inc

The stock symbol (also called stock or share ticker) of MacroGenics Inc is MGNX

The IPO of MacroGenics Inc took place on 2013-10-10

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$56.58
-2.36
-4%
TVS SRICHAKRA LTD.-$ (TVSSRICHAK)
$2980.5
-61.9
-2.03%
Savara Inc (SVRA)
$3.75
-0.06
-1.57%
$980.35
-59.45
-5.72%
$1172.1
-36.5
-3.02%
$0.02
0
0%
$12.59
-0.59
-4.48%
UCO Bank (UCOBANK)
$33.69
-2.96
-8.08%
$266.4
26.1
+10.86%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company’s pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

Address

9704 Medical Center Drive, Rockville, MD, United States, 20850